Repligen Earnings Double As Sales Growth Accelerates; RGEN Stock Nears Buy Point

Early Tuesday, Repligen reported adjusted earnings of 68 cents per share on $142.8 million in sales for its first quarter. In response, RGEN stock rose.


On average, analysts polled by FactSet expected Repligen (RGEN) to earn 42 cents per share and $117 million in sales.

In the year-ago period, Repligen earnings were 32 cents per share and the bioprocessing tools company had $76.1 million in sales.  EPS rose 113% while revenue leapt 88%, the third straight quarter of accelerating top-line growth.

For the year, Repligen guided to EPS of $2.21-$2.28 on revenue of $565 million to $590 million. Analysts called for Repligen earnings of $1.91 per share and $510 million in sales.

In premarket trading on the stock market today, RGEN stock rose 3.7% to 215.75. RGEN stock is consolidating with a handle buy point of 223.13.

Shares have a best-possible EPS Rating of 99, putting RGEN stock in the top 1% of all stocks in terms of profitability.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Vaxart Stock Plummets On Growing Losses As Investors Eye Covid Pill

Vaccine Hesitancy Ticks Down — Here’s What That Means For Covid Stocks

Short-Term Trades Can Add Up To Big Profits. IBD’s SwingTrader Shows You How

Learn How To Time The Market With IBD’s ETF Market Strategy

Options Trading: How To Start Using Options, How To Manage Risk

Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button